Celcuity(US:CELC)2026-03-10 19:22Summary of Celcuity Conference Call Company Overview - Company: Celcuity (NasdaqCM:CELC) - Focus: Development of a platform to isolate and quantify the activity of live patient tumor cells to identify responsive patients for targeted therapies, particularly in the PI3K space with the drug gedatolisib, a pan-PI3K/mTOR inhibitor [7][8] Key Points and Arguments Clinical Development - Phase 3 Studies: Completed one phase three study and has another upcoming report in the second line study for breast cancer, along with a first line study in progress [7][8] - Efficacy of Gedatolisib: - Demonstrated unprecedented efficacy in the second line setting with a median progression-free survival (PFS) of 9.3 months compared to 2 months for fulvestrant, with a hazard ratio of 0.24 [34] - Early phase data showed a median PFS of 14.5 months in a cohort of patients with PIK3CA mutations, indicating potential for significant clinical relevance [36][37] - Targeting the PAM Pathway: Gedatolisib is believed to effectively target the PAM pathway, which has been suboptimally targeted by other drugs, leading to modest efficacy in a subset of patients [14][15] Market Landscape - Current Treatments: The current standard of care for HR-positive breast cancer patients is yielding limited results, with existing therapies like fulvestrant and AI not showing significant improvements [25][26] - Impact of Competitors: Recent failures of other oral SERDs in clinical trials provide clarity on treatment regimens and highlight the potential for gedatolisib to fill the gap in treatment efficacy [27][28] Future Studies and Expectations - Upcoming Data: Expected to report data on the mutant population by the end of the current quarter or next quarter, with a focus on achieving statistically significant results [36][37] - Frontline Study: A phase 3 study targeting HR-positive, treatment-naive patients is in progress, with a safety run-in evaluating gedatolisib combined with ribociclib [55][57] Commercial Strategy - Sales Force Preparation: The company is preparing to build a sales force, targeting around 90 representatives, to effectively reach healthcare providers [63][64] - Market Access: The intravenous formulation of gedatolisib is expected to facilitate easier reimbursement pathways compared to oral drugs, enhancing market access [67] International Expansion - Regulatory Strategy: Plans to submit a Marketing Authorization Application (MAA) in Europe following the mutation data submission to the FDA, with a focus on major markets including the EU and Japan [81][82] Additional Insights - Prostate Cancer Program: Gedatolisib is also being evaluated in combination with darolutamide for prostate cancer, showing promising early results [70][71] - Potential for Other Tumor Types: There is interest in exploring gedatolisib's efficacy in endometrial cancer, although the landscape is complicated by the use of PD-1 drugs [74] Intellectual Property - Patent Exclusivity: The company expects patent term exclusivity through 2042 based on dosing patents, which are critical for optimizing treatment outcomes [76][77] This summary encapsulates the key points discussed during the Celcuity conference call, highlighting the company's strategic direction, clinical developments, and market positioning.